125 related articles for article (PubMed ID: 26857078)
21. Pharmacokinetic/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole-Candida interactions.
Li Y; Nguyen MH; Schmidt S; Zhong L; Derendorf H; Clancy CJ
Int J Antimicrob Agents; 2009 Sep; 34(3):240-5. PubMed ID: 19339162
[TBL] [Abstract][Full Text] [Related]
22. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
23.
Zhao M; Lepak AJ; VanScoy B; Bader JC; Marchillo K; Vanhecker J; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378706
[TBL] [Abstract][Full Text] [Related]
24. Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis.
Gil-Alonso S; Jauregizar N; Eraso E; Quindós G
PLoS One; 2015; 10(7):e0132730. PubMed ID: 26168269
[TBL] [Abstract][Full Text] [Related]
25. In vitro effectiveness of anidulafungin against Candida sp. biofilms.
Rosato A; Piarulli M; Schiavone BP; Catalano A; Carocci A; Carrieri A; Carone A; Caggiano G; Franchini C; Corbo F; Montagna MT
J Antibiot (Tokyo); 2013 Dec; 66(12):701-4. PubMed ID: 24022607
[TBL] [Abstract][Full Text] [Related]
26. Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.
Bader JC; Lakota EA; Flanagan S; Ong V; Sandison T; Rubino CM; Bhavnani SM; Ambrose PG
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555634
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the in vitro activity of echinocandins against Candida albicans, Candida dubliniensis, and Candida africana by time-kill curves.
Gil-Alonso S; Jauregizar N; Cantón E; Eraso E; Quindós G
Diagn Microbiol Infect Dis; 2015 May; 82(1):57-61. PubMed ID: 25703894
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.
Lepak AJ; Marchillo K; Andes DR
Antimicrob Agents Chemother; 2015 Feb; 59(2):1265-72. PubMed ID: 25512406
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of Caspofungin combined with Fluconazole on mixed Candida albicans and Candida glabrata biofilm.
Pesee S; Angkananuwat C; Tancharoensukjit S; Muanmai S; Sirivan P; Bubphawas M; Tanarerkchai N
Med Mycol; 2016 May; 54(4):384-93. PubMed ID: 26768371
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
[TBL] [Abstract][Full Text] [Related]
31. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.
Lepak AJ; Marchillo K; VanHecker J; Diekema D; Andes DR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5642-8. PubMed ID: 24002092
[TBL] [Abstract][Full Text] [Related]
32. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Gumbo T; Drusano GL; Liu W; Ma L; Deziel MR; Drusano MF; Louie A
Antimicrob Agents Chemother; 2006 Nov; 50(11):3695-700. PubMed ID: 16954319
[TBL] [Abstract][Full Text] [Related]
33. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.
Dupont H; Massias L; Jung B; Ammenouche N; Montravers P
J Antimicrob Chemother; 2017 May; 72(5):1429-1432. PubMed ID: 28088767
[TBL] [Abstract][Full Text] [Related]
35. Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.
Venisse N; Grégoire N; Marliat M; Couet W
Antimicrob Agents Chemother; 2008 Mar; 52(3):937-43. PubMed ID: 18180347
[TBL] [Abstract][Full Text] [Related]
36. In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging Candida Species.
Mahmoudi S; Rezaie S; Daie Ghazvini R; Hashemi SJ; Badali H; Foroumadi A; Diba K; Chowdhary A; Meis JF; Khodavaisy S
Mycopathologia; 2019 Oct; 184(5):607-613. PubMed ID: 31401757
[TBL] [Abstract][Full Text] [Related]
37. [In vitro antifungal activity of anidulafungin].
Quindós G; Eraso E
Rev Iberoam Micol; 2008 Jun; 25(2):83-91. PubMed ID: 18473502
[TBL] [Abstract][Full Text] [Related]
38. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
39. Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.
Li Y; Nguyen MH; Derendorf H; Cheng S; Clancy CJ
Antimicrob Agents Chemother; 2007 Aug; 51(8):2985-7. PubMed ID: 17517840
[TBL] [Abstract][Full Text] [Related]
40. [The comparison of susceptibility of Candida albicans and Candida glabrata to miconazole].
Kurnatowski P; Makieło L; Horwatt-Bozyczko E
Wiad Parazytol; 2001; 47(4):867-73. PubMed ID: 16886440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
